Prostate Cancer Treatment Market – Know Latest Trends & Forecast for Long-Term Business Planning Up to 2026 - re:Jerusalem

-

Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer.

The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Download Free Report Sample @ https://ift.tt/37hUVcV

The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of prostate cancer, increase in demand for prostate cancer treatment products, strong emerging pipeline drugs, availability of new prostate cancer treatments, and increase in awareness among people regarding the treatments of prostate cancer. In addition, surge in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings, rise in geriatric population, improved R&D investment by drug innovators, rise in generic products, increase in healthcare expenditure in the developed and developing regions, growth in pharmaceutical industries & diagnostic centers across the globe are expected to further drive the growth of the global prostate cancer treatment market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to restrain the growth of the market.

Based on drug type, the prostate cancer treatment market is categorized into chemotherapy, biological therapy, and hormone therapy. Presently, hormone therapy segment dominates the global market, and is anticipated to continue this trend during the forecast period. The key factors that drive the prostate cancer treatment market growth include rise in prevalence of prostate cancer coupled with growing public awareness regarding the treatments of prostate cancer, surge in demand for hormone therapy drugs, availability of generic drugs, and increase in number of pharmaceutical companies across the globe.

Based on distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of market share, owing to rise in number of hospitalized prostate cancer patients, convenience offered by them, and strong presence of hospital pharmacies across the globe. The online pharmacies is the fastest growing segment, at a CAGR of 6.4% from 2019 to 2026, owing to increase in preference for online purchasing of drugs over the traditional methods, increase in awareness regarding online pharmacies, and rise in number of internet users.

North America accounted for approximately one-half of the global prostate cancer treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of prostate cancer treatment products, large presence of pharmaceutical companies, well developed healthcare infrastructure, and wide availability of prostate cancer treatment drugs. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.

Inquire before buying @ https://ift.tt/2SkkiH0

The Major Key Players Are:

Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.

Key Findings of the Study:

  • Based on drug type, the hormone therapy segment held more than one-third share in the global prostate cancer treatment market in 2018.
  • Based on distribution channel, the hospital pharmacies segment held more than half share in the global market in 2018.
  • Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.6% during the forecast period.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://ift.tt/1fjYnIP



Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more